Court to decide how specific a patent disclosure must be

The Supreme Court will consider whether Amgen's patent on monoclonal antibodies that lower "bad" cholesterol is too broad to be valid under federal patent laws, specifically whether the enablement requirement in U.S. patent laws is satisfied, and this case will set a precedent on whether broad "genus" patents will remain viable in the pharmaceutical, chemical, and biotech fields.

Bild durch KI erstellt